- Home
- LXP vs RLAY Comparison
LXP vs RLAY Comparison
Compare LXP & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXP | RLAY |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LXP | RLAY |
|---|---|---|
| Price | $52.67 | $12.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $51.88 | $19.50 |
| AVG Volume (30 Days) | 423.5K | ★ 3.0M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.58% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.00 | $324.03 |
| P/E Ratio | $26.35 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $7.64 | $2.75 |
| 52 Week High | $52.79 | $17.32 |
Technical Indicators
Market Signals| Indicator | LXP | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 62.05 | 44.88 |
| Support Level | $48.19 | $9.16 |
| Resistance Level | N/A | $17.32 |
| Average True Range (ATR) | 1.21 | 0.96 |
| MACD | 0.09 | -0.41 |
| Stochastic Oscillator | 96.51 | 18.06 |
Price Performance
Historical ComparisonAbout LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. The majority of the revenue is earned through rental revenue.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.